Building on its oncology presence, AstraZeneca has partnered with Accent Therapeutics on targeting RNA-modifying proteins (RMPs) for the treatment of cancer in a deal worth up to US$1.2 B. Research has shown a variety of RMPs that are implicated in human cancers, whereby the increased levels of RMPs leads to ‘signature’ modifications that support tumour growth and survival. The deal, which is Accent’s first to date, comes less than two months after the company raised $63 M in Series B financing to advance its lead programmes into clinical development.